About TheraSkin®: TheraSkin® is a biologically active cryo-preserved human skin allograft for non-responsive chronic wounds. Its fully developed extracellular matrix (ECM) and living cells provide an "at-ready" supply of human growth factors, cytokines and collagen to jumpstart wound healing. TheraSkin® not only provides necessary growth factors and cytokines to treat chronic wounds, it also provides a large quantity of essential types of human collagens, in appropriate ratios, to support healing. This allows TheraSkin® to be used on more severe wounds with exposed bone, tendon, joint capsules or muscle.
| Website | http://theraskin.com |
| Revenue | $1 million |
| Employees | View employees |
| Competitors | Lumenis, Revance, SkinCeuticals, Obagi, Epionce / Episciences, Inc., Prollenium Medical Technologies Inc., Hale and Hearty Soups, Aesthetics Biomedical® Inc, Dermaroller - The Original, Sente Inc +21 more (view full list) |
Looking for a particular TheraSkin employee's phone or email?
TheraSkin Questions
The TheraSkin annual revenue was $1 million in 2026.
